Bloomberg Law
Jan. 30, 2021, 12:01 PM

Multiple Covid-19 Vaccine Protections Pose Messaging Challenge

Jeannie Baumann
Jeannie Baumann

Varying protection levels in forthcoming Covid-19 vaccines could pose a messaging challenge for public health leaders racing to achieve high vaccination levels.

Johnson & Johnson Inc. released interim results Friday showing its vaccine was 66% effective in preventing severe and moderate cases of Covid-19, with a 72% protection level in the U.S. That’s lower than the 90%-plus efficacy rates of the Pfizer/BioNTech and Moderna vaccines currently in circulation.

“A 70% or 75% effective rate is still really wonderful. It is on par even above some of the other vaccines that we use all the time,” Katharine J. Head, an associate ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.